ClinicalTrials.gg
TerminatedNCT02037347Updated Nov 30, 2016Results posted

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

A Phase 1/2 interventional study of Palifermin in Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome, sponsored by Brett King. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-30.

Sponsored by Brett King · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Low enrollment numbers precluded completion of the study during a reasonable amount of time.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Stevens-Johnson Syndrome with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Stevens-Johnson Syndrome · United States.

Enrollment
5th of 10
1 · median 1
Started
2010
with 1 other
Phase 1/2
5 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
1 of 11
Brett King

Among the 11 studies in Stevens-Johnson Syndrome with a site in United States, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2010, is one of 5 in phase 1/2, and was the 4th registered.

Stevens-Johnson Syndrome

40 studies on the registry are indexed under Stevens-Johnson Syndrome; 8 are open to participants now.

Browse Stevens-Johnson Syndrome studies →

Open to participants now

1 of the 11 studies in Stevens-Johnson Syndrome with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Stevens-Johnson Syndrome studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Stevens-Johnson Syndrome with a site in United States, or all of them as a file.
02

Study summary

To test the ability of palifermin (a recombinant human keratinocyte growth factor) to decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Overlap, diseases in which there is extensive sloughing of the skin and mucosa, including that of the eyes, gastrointestinal tract, respiratory and genitourinary systems.

03

Conditions studied

  • Toxic Epidermal Necrolysis
  • Stevens-Johnson Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Skin in early disease showing apoptotic keratinocytes in the epidermis and in more advanced disease necrosis of the entire epidermis
  • Epidermal detachment or erythematous to purpuric macules involving more than 10% of body surface area in addition to involvement of the oropharynx; there may be further involvement of other mucosal surfaces, ie. conjunctivae, gastrointestinal tract, respiratory and genitourinary epithelia
  • Age of 18 years old or older
  • The patient is expected to survive longer than 48 hours

Exclusion criteria

Exclusion Criteria:

  • Skin detachment above 90% of the body surface area
  • Skin detachment has not progressed during the previous 48 hours
  • A positive serum pregnancy test
  • Age \< 18 years old
  • Known hematologic or solid organ
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Palifermin

    Palifermin 60 micrograms/kg/day IV for 3 consecutive days

    Drug: Palifermin

Interventions

06

What researchers measure

Primary outcomes

  1. Time-to-cutaneous Re-epithelialization

    Time frame: The number of days between the start of palifermin administration and complete re-epithelialization of skin up to 14 days

Secondary outcomes

  1. Time-to-mucosal Re-epithelialization

    Time frame: The number of days between the start of palifermin administration and complete re-epithelialization of oral mucosa up to 14 days

  2. Time-to-cessation of Epidermal Necrosis

    Time frame: The number of days between the start of palifermin administration and cessation of further epidermal necrosis up to 14 days

07

Results

Posted Nov 30, 2016

Participant flow

Participant flow — Overall Study
MilestonePalifermin
Started1
Completed1
Not completed0

Outcome measures

PrimaryTime-to-cutaneous Re-epithelialization
Time frame:
The number of days between the start of palifermin administration and complete re-epithelialization of skin up to 14 days
Reported as:
Number · days
Time-to-cutaneous Re-epithelialization
daysPalifermin
Time-to-cutaneous Re-epithelialization6
SecondaryTime-to-mucosal Re-epithelialization
Time frame:
The number of days between the start of palifermin administration and complete re-epithelialization of oral mucosa up to 14 days

No measurements were reported for this outcome.

SecondaryTime-to-cessation of Epidermal Necrosis
Time frame:
The number of days between the start of palifermin administration and cessation of further epidermal necrosis up to 14 days
Reported as:
Number · days
Time-to-cessation of Epidermal Necrosis
daysPalifermin
Time-to-cessation of Epidermal Necrosis3

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Palifermin—1/1 (100%)0/1 (0%)
Most frequent serious events
Most frequent serious events
EventPalifermin
ischemic necrosisGastrointestinal disorders1/1

Baseline characteristics

73-year-old male.

Age, Customized
Age, Customized(years)Palifermin
Age73
Sex/Gender, Customized
Sex/Gender, Customized(participants)Palifermin
Male1
08

Study locations

2 sites
  • Bridgeport Hospital
    Bridgeport, Connecticut 06610, United States
  • Yale-New Haven Hospital
    New Haven, Connecticut 06510, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2014
First posted
Jan 15, 2014
Start
Oct 2010
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Nov 30, 2016
Last update
Nov 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02037347
Lead sponsor
Brett King
Responsible party
Brett King (Assistant Professor of Dermatology, Yale University) — Sponsor-investigator
First posted
Jan 15, 2014
Start date
Oct 2010
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Nov 30, 2016
Last update
Nov 30, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fibroblast Growth Factor 7

Start the discussion